2441 results about "Glucose blood" patented technology

A method for guiding a user to select a dose of insulin, including the steps of calculating a firsts pecific dose of insulin by applying information provided by the user to an insulin dose calculation algorithm, wherein such information includes at least the user's current blood glucose level and the user's desired blood glucose level, calculating at least a second specific dose of insulin that is different from the first specific dose, and presenting to the user a range of doses comprising at least two of the specific doses.

A system to assist an individual in developing a therapy in diabetes treatment of a patient includes a user interface control module, a simulation engine, a charting and display module. The user interface control module receives an input related to the patient and captures a current time of the simulation. The simulation engine receives the input, generates a plurality of blood glucose readings for the patient up to the current time of the simulation based on the input, and to transfers the plurality of blood glucose readings. The charting and display module receives the plurality of blood glucose readings and display the plurality of blood glucose readings. The simulation engine receives patient parameters from a patient parameter library based on a selected patient model.

A system is provided for monitoring blood glucose data of a patient. The system includes a sensing device and hospital monitor. The sensing device includes a sensor and sensor electronics and is adapted to transmit information to the hospital monitor while continuing to sense blood glucose data. The communication between the sensing device and the hospital monitor may be wireless. The sensor electronics may include a sensor power supply, a voltage regulator, and optionally a memory and processor.

A system is provided for sensing blood glucose data of a patient. The system includes a sensor, user interface, and an optional auxiliary device. If the connection between the sensor and user interface is by a wire, the sensor remains powered when the wire is disconnected. The communication between the sensor and the user interface may be wireless. The auxiliary device can be a patient monitor or other display or signal device, which displays information about the blood glucose data collected by the sensor. The sensor is connected to sensor electronics, which include a sensor power supply, a voltage regulator, and optionally a memory and processor.

A method, system, and computer program product related to the diagnosis of diabetes, and is directed to predicting the long-term risk of hyperglycemia, and the long-term and short-term risks of severe hypoglycemia in diabetics, based on blood glucose readings collected by a self-monitoring blood glucose device. The method, system, and computer program product pertain directly to the enhancement of existing home blood glucose monitoring devices, by introducing an intelligent data interpretation component capable of predicting both HbA1c and periods of increased risk of hypoglycemia, and to the enhancement of emerging continuous monitoring devices by the same features. With these predictions the diabetic can take steps to prevent the adverse consequences associated with hyperglycemia and hypoglycemia.

A method of providing performance reports to persons associated with the monitoring of an analyte level, such as blood glucose concentrations in a host, is provided. The performance reports can indicate a measure of an analyte variability of the host over a first analysis time period compared to a measure of analyte variability of the host over one or more other analysis time periods. The analyte level of the host can be received in each of a plurality of sensor readings from a continuous analyte sensor, such as multiple sensor readings per hour, so that the analyte variability that is used in determining the performance report of the host can be based on not just a few metered readings taken by the host, but a plurality of intermittent readings that are taken by a continuous analyte sensor, for example. Various types of performance reports can be generated, such as reports that comprise charts, graphs, tables, and / or other visual indicia of a host's performance during one analysis period versus another analysis period.

The present invention relates to novel peptide conjugates which have increased stability and are useful in the treatment of excess levels of blood glucose.

An automatic skin puncturing system that was operable with one hand for allowing individuals with the use of only a single hand to take the blood samples needed to monitor their blood glucose levels. The automatic skin puncturing system includes a housing assembly, a power connecting jack, a battery holder, an indexable, motor driven turntable, an index switch, a reed switch, a lancet lifting assembly, a disposable lancet carousel cartridge, and an electronic, micro-processor controlled circuit.

The invention provides nutritional supplements for an oral or enteral administration to humans, whether in satisfactory health, or having a medical condition. These supplements can provide humans with a complete, balanced nutrition in a bioavailable form, either as a food supplement or as a meal replacement, and preferably includes one or more slow-digesting carbohydrates that renders them effective in maintaining blood glucose levels at, or returning abnormal blood glucose levels to, normal blood glucose levels. Nutritional supplements within the invention can be employed with humans that are diabetic, borderline diabetic, pregnant and / or lactating, geriatric humans and humans that have, are at risk for, or develop other glucose intolerance or cardiovascular disease.

A system for measuring a glucose level in a blood sample includes a test strip and a meter. The test strip includes a sample chamber, a working electrode, a counter electrode, fill-detect electrodes, and an auto-on conductor. A reagent layer is disposed in the sample chamber. The auto-on conductor causes the meter to wake up and perform a test strip sequence when the test strip is inserted in the meter. The meter uses the working and counter electrodes to initially detect the blood sample in the sample chamber and uses the fill-detect electrodes to check that the blood sample has mixed with the reagent layer. The meter applies an assay voltage between the working and counter electrodes and measures the resulting current. The meter calculates the glucose level based on the measured current and calibration data saved in memory from a removable data storage device associated with the test strip.

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient's diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

A diabetes management system or process is provided herein that may be used to analyze and recognize patterns for a large number of blood glucose concentration measurements and other physiological parameters related to the glycemia of a patient. In particular, a method of monitoring glycemia in a patient may include storing a patient's data on a suitable device, such as, for example, a blood glucose meter. The patient's data may include blood glucose concentration measurements. The diabetes management system or process may be installed on, but is not limited to, a personal computer, an insulin pen, an insulin pump, or a glucose meter. The diabetes management system or process may identify a plurality of pattern types from the data including a testing / dosing pattern, a hypoglycemic pattern, a hyperglycemic pattern, a blood glucose variability pattern, and a comparative pattern. After identifying a particular pattern with the data management system or process, a warning message may be displayed on a screen of a personal computer or a glucose meter. Other messages can also be provided to ensure compliance of any prescribed diabetes regiments or to guide the patient in managing the patient's diabetes.

Methods and apparatus are provided for determining a diabetic patient's carbohydrate to insulin ratio (CIR), carbohydrate to blood glucose ratio (CGR), and insulin sensitivity factor (ISF) using the patient's record of blood glucose readings, carbohydrate consumption and insulin doses. The method provides the sensitivity factors that best account for the patient's observed blood glucose changes by linear regression of appropriately transformed variables. An apparatus that can collect and store the blood glucose readings, insulin dosages, and carbohydrate intake data and process these data according to this invention can generate statistically characterized sensitivity factors to advise the diabetic patient on optimal bolus insulin dosages.

A test device for testing of analyte concentration in a fluid to be applied thereto, the device comprising a plurality of test members arranged in at least one stack and electrodes for engaging with electrode tracks on a test member. A pusher pushes a single test member from the stack so that it can engage with the electrodes. An actuation member is connected to the pusher, and moves it when operated by a user. The at least one stack of test members is enclosed in a magazine which is initially sealed by a moisture impermeable seal. A cutter is provided for slitting the seal and permitting a test member to be pushed from the magazine by the pusher when the first test member from the magazine is to be used.

A method of displaying medical data, particularly data representative of the condition of patients suffering from chronic medical conditions such as asthma, diabetes and hypertension. The display consists of two graphical elements, one of which indicates the current value of a parameter indicative of the patient's condition, this being displayed against another graphical element which represents a model of normality for that patient. The graphical element indicating the current condition may be, for example, a needle, against a scale which is constructed according to the patient-specific model of normality. This is particularly advantageous in the case of displays which have a small display area, such as mobile telephones and PDAs. Other forms of display are disclosed, such as histograms with the display being dynamically colour-coded and auto-scaled, or displays including limits which may vary. Another form of display is also disclosed which illustrates administrations of a pharmacological agent and corresponding measurements of the patient's condition, with a visual link such as colour-coding linking the administration to the corresponding condition measurement. For example several days of insulin administration dosages may be displayed alongside several days of blood glucose measurements, with the administrations colour-coded to the corresponding blood glucose measurement, to assist the patient in determining whether the insulin administration is stably controlling their condition.

A system and method for providing optimal insulin injections to a subject, using a controller, a continuous glucose monitor, and an insulin delivery unit is disclosed. The controller possesses a discrete-time, linear model predictive control law, means for sending information to the insulin delivery unit, and means for receiving information from the CGM. The control law implemented is derived from a discrete-time model of glucose insulin dynamics and an aggressiveness parameter. The result is that using only glucose measurements obtained from sensor readings and, prior values of external insulin infusion and meal and exercise announcement the optimal insulin injection necessary to safely regulate blood glucose can be calculated.

A glucose monitoring kit for storing, carrying and using a blood glucose monitoring system, which includes a meter, a container for storing test strips and at least one sampler, is configured with case having two halves pivotal relative to one another, and a retention system. The retention system includes a plurality of clips arranged so that the first clip extends along the central region of the case between the two halves and second and third clips coupled to one of the halves. At least one of the first, second and third clips is made from hard polymeric material and configured to removably receive the meter so that the meter can be used by the operator of the monitoring system while being retained in the at least one clip

The invention relates to a method of food and insulin dose management for a diabetic subject, comprising:providing an intended insulin unit value or an intended carbohydrate unit value representing the amount of insulin or carbohydrate intended for intake by the subject; anddetermining the balance value of either insulin units or carbohydrate units needed to balance with the provided unit value and maintain blood sugar in the subject in a target blood sugar range.

A sensor array designed to be continuously indexed through a compatible blood glucose test monitor for the purpose of conducting multiple consecutive blood glucose measurements. The sensor array can be configured to substantially conform to a non-planar surface. In one embodiment, the sensor array includes first and second test sensors which are hingedly coupled together through a pin and socket interconnection. In another embodiment, the sensor array includes a unitary, non-conductive substrate which is scored to define one or more fold lines, a first set electrodes deposited on the substrate to define a first test sensor, and a second set of electrodes deposited on the substrate to define a second test sensor. In another embodiment, the sensor array includes a first test sensor, a second test sensor spaced apart from said first test sensor, a first spacer mounted on the first test sensor, a second spacer mounted on the second test sensor, and a unitary flexible member disposed across said first and second spacers.

A monitoring system for monitoring the glucose level of a subject having a glucose level history is disclosed. The system comprises (a) a non-invasive measuring device, operable to measure and record an electrical quantity from a section of the subject body, so as to provide a time-dependence of the electrical quantity over a predetermined time-period. The system further comprises (b) a processing unit, communicating with the non-invasive measuring device. The processing unit comprises: an extractor, for extracting a plurality of parameters characterizing the time-dependence, a correlation function calculator for calculate a subject-specific correlation function, and an output unit, communicating with the correlation function calculator and configured to output the glucose level of the subject. The subject-specific correlation function describes the glucose level history and is defined over a plurality of variables, each corresponding to a different parameter.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

The present invention relates to a blood analyte measurement system for the procurement of blood samples for measurement of blood properties such as analyte concentration or analyte presence. A blood access system can be coupled with a measurement system such as an electrochemical sensor, and can also be used with other measurement modalities. Embodiments of the present invention can facilitate accurate measurement of blood glucose by the clinician in a sterile manner. Embodiments of the present invention can also enable the calibration of the sensor at one or more calibration points. One desired analyte of measurement is glucose for the effective implementation of glycemic control protocols. Embodiments of the present invention can also be used for the measurement of other analytes such as arterial blood gases, lactate, hemoglobin, potassium and urea. Additionally, embodiments of the present invention can function effectively on a variety of blood access points and specifically enables glucose monitoring in an existing arterial line that is already in place for hemodynamic monitoring. The present invention does not consume a significant amount of blood. Some embodiments of the present invention can re-infuse the blood into the patient, which can facilitate operation of the system in a sterile manner.

Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.

A system, computer program product, method and algorithm for evaluation of blood glucose variability—one of the most important parameters of diabetes management. An embodiment of the method may use routine self-monitoring blood glucose (SMBG) data collected over a period of 2-6 weeks, for example, based on a theory of risk analysis of blood glucose data. One aspect may include a method, system and computer program product for computing the Average Daily Risk Range (ADRR)—a measure of overall glucose variability. Another aspect may include a method, system, and computer program product for estimating separately the glucose variability in the hypoglycemic range via a Low BG Index (LBGI) and the glucose variability in the high BG range via High BG Index (HBGI) followed by a combination of the two indices into a single variability display.

Disclosed is a method and the resulting product thereof comprising a solid light-conducting fiber with a point of attachment and having a textured surface site consisting a textured distal end prepared by being placed in a vacuum and then subjected to directed hyperthermal beams comprising oxygen ions or atoms. The textured distal end comprises cones or pillars that are spaced upon from each other by less than 1 micron and are extremely suitable to prevent cellular components of blood from entering the valleys between the cones or pillars so as to effectively separate the cellular components in the blood from interfering with optical sensing of the glucose concentration for diabetic patients.